Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors Meeting Abstract
| Authors: | Sharma, M. R.; Carvajal, R. D.; Catenacci, D.; Emens, L. A.; Hanna, G. J.; Juric, D.; Kang, Y. K.; Lee, J.; Lee, K. W.; Li, B. T.; Moore, K.; Pegram, M. D.; Pohlmann, P. R.; Rasco, D.; Spira, A.; Heeke, A. L.; Wang, D.; Garbo, L.; Manda, S.; Sachdev, J.; Ackerman, S. E.; LeBlanc, H.; Dornan, D.; Kowanetz, M.; Alonso, M. N.; Husain, A.; Perez, E. A.; Dumbrava, E. I. |
| Abstract Title: | Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors |
| Meeting Title: | 112th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2021 Apr 10-15/May 17-21 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-07-01 |
| Language: | English |
| ACCESSION: | WOS:000680263501300 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2021-CT218 |
| Notes: | Meeting Abstract: CT218 -- Due to Covid 19 pandemic, the conference was held virtually -- Source: Wos |
